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ABSTRACT 
 
Introduction: Diabetes Control and Complications Trial has established the 
importance of glycemic control in reducing the progression of retinopathy, nephropathy, 
and neuropathy in type 1 diabetics. There is little literature linking the frequency of 
glycemic monitoring with glycated hemoglobin A (HbA1c) in type 2 diabetics. The 
objectives were to assess the influence of glycemic self-monitoring on HbA1c in three 
groups of patients with type 2 diabetes (with insulin, with oral antidiabetics and with 
combination therapy).  
Methods: The glucometer capillary surveys of 117 patients were counted in the 30 
days prior to the visit to the Integrated Diabetes Unit at Centro Hospitalar Tondela-Viseu. 
In the three groups considered, sociodemographic characteristics (age, gender, area of 
residence, household and schooling) were evaluated and compared.  
Results: There was no statistically significant association between HbA1c and the 
frequency of capillary glucose in any of the groups. In the evaluation of sociodemographic 
data, contrary to what was expected, the area of residence and schooling did not influence 
the value of HbA1c.  
Conclusion: These results question the role of glycemic monitoring in the metabolic 
control of type 2 diabetics, highlighting the need to implement therapeutic education 
programs so that these patients can adequately intervene in the therapeutic adjustment as a 
function of the information obtained by capillary glycemia. 
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INTRODUCTION 
 
Following the Diabetes Control and Complications Trial [1], the importance of 
glycemic control in reducing the progression of retinopathy, nephropathy and diabetic 
neuropathy in type 1 diabetics, as well as a strong correlation between the frequency of 
capillary glycemic monitoring (CGM) with glycated hemoglobin A (HbA1c) in type 1 
diabetics [2], was well established. The lack of perception and appreciation by diabetic 
patients of macro and microvascular complications remains an obstacle to ambitious 
glycemic control
 
[3-6]. 
Capillary glycemic self-monitoring is a valuable instrument because it allows the 
definition of individualized controlled objectives, being essential in the therapeutic 
education of the person with diabetes [7]. 
There is little literature that relates the frequency of CGM with HbA1c in type 2 
diabetics [8]. The studies conducted are not consensual. The Kumamoto Study has 
demonstrated that intensive glycemic control may delay the onset and progression of 
microvascular complications in Japanese type 2 diabetic patients [9]. Another study 
concludes that CGM should be based on individualized and motivational goals and that 
family support and gender do not influence the frequency of CGM nor the reduction of 
HbA1c [8]. Another study [10], which compares a group of diabetics who self-monitor 
capillary glycemia with another who does not, concludes that CGM is associated with 
better glycemic control irrespective of type of diabetes and medication. The influence of 
sociodemographic characteristics on glycemic control is not well defined [8], and the 
purpose of this study was to evaluate the influence of age, gender, area of residence, 
residing alone and schooling in the value of HbA1c. 
The impact of glycemic monitoring on anxiety and depression in patients initiating 
insulin therapy has also been studied and it has been concluded that there is no relationship 
between mood disorders and glycemic control [11]. Similarly, progressive aging of the 
population and increasing institutionalization, especially of vulnerable patients, should 
include adequate glycemic control with individualized needs that allow a balance between 
metabolic control and risk of hypoglycaemia [12,13]. 
 
 
The aim of the study was to assess the influence of glycemic self-monitoring on 
HbA1c in three groups of patients with type 2 diabetes: treated with insulin only, treated 
with oral antidiabetics only and in combination therapy. 
 
 
 
MATERIALS AND METHODS 
 
 This study obtained a favorable opinion from the Ethics Committee of the Tondela-
Viseu Hospital Center and was approved by the Board of Directors. All patients were 
elucidated and clarified regarding the objectives of the study and their informed consent 
was requested. 
A total of 140 patients were included and 117 questionnaires were validated for type 
2 diabetic patients attending the consultations at the Diabetes Unit of the Tondela-Viseu 
Hospital Center. Glucometer recordings were evaluated in the month prior to the 
consultation. Three groups of patients were constituted according to the medication used in 
the treatment of diabetes: those treated exclusively with oral antidiabetics, those medicated 
with insulin only and those who were under combination therapy. The database 
"AlertConsult" and "SClinic" were consulted and the following parameters were recorded: 
HbA1c in the last trimester, age, sex and area of residence, schooling level and household 
through telephone calls. 
The following methodology was used: data on quantitative variables are summarized 
by mean and standard deviation or by median and inter-quartile amplitude. For qualitative 
variables, the collected data are summarized through counts and/or percentages. In each 
group studied: insulin therapy (I), oral antidiabetic therapy (O), combination therapy (I+O), 
the relationship between HbA1c and the number of capillary glycemia per month was 
analyzed using the Kendall’s tau coefficients. The relationship between glycemic control 
and sociodemographic characteristics was also investigated in each group. The Mann-
Whitney test and the Kruskal-Wallis test were used when the sociodemographic variable 
was qualitative, defining two or more groups, and the correlation coefficient was used when 
the variable was quantitative.  
 
 
Multivariate analysis was conducted to investigate the relation between HbA1c and 
the number of capillary glycemia per month while controlling for possible confounders. 
Logistic regression modelling with HbA1c less or more than 7% as dependent variable was 
performed. The number of capillary glycemia per month, gender, age, schooling and 
treatment group were considered to include the model as independent variables. Interaction 
terms to assess possible different effects of the number of capillary glycemia per month on 
each treatment group were also considered. Non-significant variables were removed from 
the model. 
A value of p <0.05 was considered statistically significant. All statistical analysis was 
carried out using SPSS
®
 statistical software. 
 
RESULTS 
 
 The sample of type 2 diabetic patients studied is composed of 3 groups depending on 
the medication used for the antidiabetic treatment: those medicated exclusively with oral 
antidiabetics (O), those medicated with insulin alone (I) and those under combination 
therapy (I+O). 
The mean age in the total sample is 62 ± 12 years, the female: male ratio is 1: 1.2 
(45.3% vs. 54.7%), 75.9% of the patients lived in rural vs. 24.1% in urban areas, 95.7% did 
not live alone, and in terms of schooling only 33.3% of patients had completed secondary 
schooling. These sociodemographic data are summarized in Table 1. 
Table 2 characterizes the sample for the three patient groups in terms of HbA1c, 
number of monthly capillary glycemia and age. There is statistical evidence that the group 
of users taking oral antidiabetic drugs has lower HbA1c, than both insulin-treated patients 
and patients treated with both therapies (Figure 1). There is no significantly differences 
between groups regarding age. The number of monthly capillary glucose is significantly 
higher in the insulin-treated group, followed by the I+O group and the group medicated 
with oral antidiabetics alone (Figure 2). 
The correlation between the number of monthly capillary glycemia and the HbA1c 
value was not statistically significant in any of the treatment groups (Kendall’s tau = 0.043, 
p = 0.751 for group I; Kendall’s tau = 0.255, p = 0.062 for O group; Kendall’s tau = -0.122, 
p = 0.17 for I+O group).  
 
 
Figure 3 illustrates the weak association observed between the two variables under 
study (HbA1c and number of glycemia/month). It should be noted that the correlation 
between HbA1c and the number of blood glycemias/month in the general sample is also not 
significant (r = 0.088, p = 0.347). 
Since there was no relationship between the two variables for any of the groups, 
another approach was attempted. The patients were divided into two groups: those with 
HbA1c ≤ 7% and those with HbA1c > 7% to try to find out if there was a significant 
association with glycemic control in any of the study groups. 
In the group with combined therapy (I+O) there was a marginally significant trend 
towards higher blood glucose self-monitoring frequency in patients with HbA1c ≤ 7%, 
compared to patients with HbA1c > 7% (p value for Mann- Whitney = 0.085). On the 
contrary, in the O group, patients with HbA1c < 7% tend to have lower CGM (p = 0.05). 
Regarding the influence of sociodemographic characteristics on glycemic control, the 
following was determined: 
 
1) Age 
 
For each group there were no significant correlations between age and HbA1c (r = 
0.072, p = 0.716 in group I, r = 0.268, p = 0.166 in group O, r = 0.051 p = 0.694 in group I 
+ O ). Thus, it is not possible to infer that age has some relation with glycemic control. 
 
 
2) Sex 
 
In the group treated with combination therapy there was a significant trend towards 
higher values of HbA1c in males (p = 0.023). In the remaining groups, HbA1c levels were 
not significantly different in males anda females (p = 0.909 and p = 0.023) - figure 4. 
 
 
3) Area of residence 
 
 
 
There was no relationship between the type of area of residence (rural or urban) and 
HbA1c values in any of the groups. 
 
 
4) Living alone 
 
Of the total number of patients in the sample few live alone (total of 5 patients), so it 
was not possible to perform correlation tests. 
 
5) Schooling 
 
There was a need to aggregate the data into two groups for statistical analysis: level 
of education up until Basic education in one group and Secondary or Higher education in 
another group. It should be noted that there were 2 illiterate patients treated with insulin and 
4 illiterate patients under combined therapy. There was no statistically significant 
association between schooling and glycemic control in any of the study groups. 
Multivariate logistic regression was used to estimate the odds of a patient being 
uncontrolled (HbA1c ≥ 7%) adjusting for gender, schooling and age (Table 3). The odds of 
belonging to the uncontrolled group (HbA1c ≥ 7%) are lower for the patients taking O 
medication, and also for the I + O group patients, compared with the I group patients. 
Furthermore, for the group of patients taking I + O medication, the odds of being an 
uncontrolled patient (HbA1c ≥ 7%) decrease with the increase of the number of capillary 
glycemia per month (Table 3). 
 
DISCUSSION 
 
A recent Italian study of 13,331 type 2 diabetic patients showed that CGM is 
underused in this type of patients treated with insulin or not [14]. In all treatment groups 
investigated, postprandial glycemia was rarely investigated, poor metabolic control with 
hyper or hypoglycemia rates were warranted, and the authors concluded that CGM in type 
2 diabetics in the real world needs an urgent improvement [14]. 
 
 
The results of our study, although representing a small sample, support that there is 
no association between the frequency of self-monitoring of capillary glycemia and HbA1c 
in any of the three groups of patients studied. The strongest correlation was found in the 
group treated with oral antidiabetics alone, but even this is not statistically significant. It 
should be noted that the correlation observed in groups I and O is positive, that is, in the 
samples of these two groups, there was a slight tendency towards higher values of HbA1c 
in individuals with more blood glucose per month. 
There are authors who argue that CGM in non-insulin treated type 2 diabetics should 
not be systematically recommended, concluded through the results of a meta-analysis in 
which evidence showed that at 6 months there was a reduction of only 0.25% in HbA1c in 
this group of patients, interpreted as having no clinical significance either in terms of 
glycemic control nor hypoglycemia [15]. In addition, the use of CGM is associated with 
enormous costs, which should be better redirected to effective health improvement 
strategies for this category of patients [16]. 
In the group of patients medicated with insulin, a slight tendency of higher HbA1c 
was observed in patients with greater number of monthly capillary glycemia performed. 
However, for the group of patients taking I + O medication, the odds of being an 
uncontrolled patient (HbA1c ≥ 7%) decrease with the increase of the number of capillary 
glycemia per month. This results may represent, on the one hand, a group of patients with 
more severe and more difficult metabolic control. Of the three groups studied, the group 
treated with insulin had the worst level of metabolic control (HbA1c 8.3%) compared to the 
group receiving oral antidiabetic drugs that had the best control (HbA1c 7.2%). The high 
incidence of patients in the Diabetes Unit with micro and macrovascular complications, 
multiple comorbidities and very difficult metabolic control is a possible explanation of 
these differences. This group of patients is mostly medicated with insulin. On the other 
hand, patients receiving oral antidiabetic drugs are preferentially referred after discharge to 
primary care. 
These data are worthy of reflection: capillary glycemia alone did not show any 
reflection at the level of HbA1c. Thus, it is implied that in patients with type 2 diabetes, 
especially insulin-treated patients due to more difficult control of the disease, we must 
implement measures of therapeutic education in order to enable patients to act on the 
information provided by glycemic control. So maybe then the results would be different. 
 
 
CGM may be an important guide to consider in a personalized way in type 2 
diabetics, insulin-treated or not, and in particular in patients with the following 
characteristics: with high levels of postprandial glucose, lack of motivation and adherence, 
risk of not acknowledging hypoglycaemia, obese type 2 diabetic patients with oral 
hypoglycaemic agents and initiation of insulin therapy, patients with coronary artery 
disease, nephropathy, and the elderly [17]. 
We can consider that there is an inertia of action of type 2 diabetic patients in the 
adjustment of insulin doses towards uncontrolled values of glycemia. Unlike type 1 diabetic 
patients, in type 2 diabetics a higher number of glycemic evaluations does not reflect better 
glycemic control. One of the possible explanations is the need to approximate the 
therapeutic education level of type 1 to type 2 diabetics, implying a greater rigor and 
autonomy in glycemic control. 
CGM leads to better glycemic control only in the context of appropriate education, 
both for patients and health care professionals, on how to respond to readings in terms of 
lifestyle and treatment adjustment [18]. Asking the patient to perform a greater number of 
capillary glycemic controls, without being able to act towards the values, can be 
counterproductive and even associated with non-compliance and withdrawal of therapy. 
Individualized therapy always associated with a structured program of therapeutic 
education will be instrumental in improving metabolic control, because the use of CGM has 
been associated with possible feelings of guilt, failure, and deception when the readings are 
not discussed and integrated into a plan in conjunction with the doctor [19]. 
Consulting the publication "Diabetes Facts and Figures 2015" [20], the last one 
relative to our country, it shows that the cost of test strips that year was 52.6 million euros, 
which corresponds to 19% of the total costs of diabetes in Portugal. Type 2 diabetes 
accounts for about 90% of diabetic patients identified consuming a large portion of these 
resources. If better metabolic control can not be achieved, it is imperative to question the 
real benefit of these costs. Thus, it seems essential for us to have a therapeutic education 
program that allows us to value the information obtained and to transform self-monitoring 
into true self-control. 
Regarding the area of residence this also had no influence on the level of HbA1c. The 
recent improvement in accessibility may justify this. One of the data from the study that 
was expected with curiosity was to assess whether residing alone was associated with an 
 
 
upper HbA1c in each of the groups. The results showed that although in an inner part of the 
country, the number of patients residing alone is very small (five), which corresponds to 
only 4.2% of the sample. There is a social concern on the part of patients and their families 
not to reside alone. 
Schooling as presumed is low (67% have basic or lower education), however, there is 
no difference in glycemic control as expected [21,22]. There is thus a compensation made 
in therapeutic education that counteracts the difference in schooling of these patient groups. 
The lowest literacy is associated with a higher prevalence of diabetes, however, in this 
group of patients the level of control is independent of their literacy level. This may 
correspond to an effort on the part of the Diabetes Unit to overcome this barrier of 
inequality or to reflect that what we ask of the users is accessible to all. 
The recent DIAMOND study [23] evaluated the effect of continuous glycemic 
monitoring in real time versus self-monitoring of capillary glycemia in glycemic control in 
insulin-treated type 2 diabetic adults with elevated levels of HbA1c, concluding that 
continuous monitoring was superior to self-monitoring of capillary glycemia, resulting in a 
greater decrease in HbA1c level, with similar benefits observed by age group, educational 
levels and numeracy capacity of participants. This may be a future solution in particular in 
type 2 diabetic patients in need of insulin therapy. 
 
CONCLUSION 
 
The review of the literature in this area made it clear that more studies are needed, 
and that the use of ambulatory self-monitoring of capillary glycemia in type 2 diabetics has 
an uncertain efficiency [24]. 
The results of our study, as well as other observational studies and meta-analyzes, 
point to the continued need for a long-term randomized controlled trial, mainly to evaluate 
the cost-effectiveness of the capillary glycemic self-monitoring test. For such studies to be 
effective it will be necessary to ensure that patients are able to monitor and appropriately 
modify behaviors in response to CGM readings. We may be unambitious in our goals for 
true self-control of people with type 2 diabetes. Self-monitoring of capillary glycemia by 
our patients is not enough. We have to evolve into a therapeutic education program that 
 
 
transforms self-monitoring into self-control, and thus obtain better metabolic control so that 
capillary glycemia research is much more than "finger pricking." 
Introducere: Controlul glicemic asupra reducerii progresiei retinopatiei, nefropatiei 
si neuropatiei în diabetul zaharat de tip 1 este cunoscut datorită studiului clinic  Diabetes 
Control and Complications Trial. În literatură sunt puține date ce asociază frecvența 
monitorizării glicemice cu novelul hemoglobinei glicozilate (HbA1c) la pacienții cu diabet 
zaharat tip 2. Obiectivele acestui studiu a fost de a evalua influența automonitorizării 
Hb1Ac în 3 grupe de pacienți cu diabet tip 2 (cu tratament cu insluină, cu antidiabetice 
orale sau cu combinația celor două).   
Materiale și metode: Analizele glucometrelor a 117 pacienți au fost luate în 
considerare cu 30 de zile înaintea vizitei la Spitalul Tondela-Viseu, Portugalia. În cele trei 
grupuri considerate au fost înregistrate caracteristicile sociodemografice (gen, vârstă, 
mediul de proveniență, nivel educațional) 
Rezultate: Nu au fost găsite diferențe semnificative statistic între frecvența 
monitorizării glicemiei capilare și HbA1c. Contrar așteptărilor mediul de proveniență și 
nivelul educational nu au influențat valoarea HbA1c.  
Concluzii: Aceste rezultate evidențiază necesitatea implementării programelor 
educaționale astfel încât acești pacienți să poată interveni adecvat în ajustarea terapiei 
medicamentoase bazându-se pe datele obținute la măsurarea glucozei capilare.  
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Table 1: Characterization of the sample by sociodemographic data and division by 
treatment groups. 
 
Sociodemographic Data 
Diabetes Therapy 
I O I + O Total 
N % N % N % N % 
Sex F 12 42.9 11 39.3 30 49.2 53 45.3 
M 16 57.1 17 60.7 31 50.8 64 54.7 
Area of 
Residence 
Rural 13 46.4 23 82.1 52 86.7 88 75.9 
Urban 15 53.6 5 17.9 8 13.3 28 24.1 
Living 
alone 
Yes 2 7.1 1 3.6 2 3.3 5 4.3 
No 26 92.9 27 96.4 59 96.7 112 95.7 
Schooling Basic or 
none 
13 46.6 19 67.9 46 75.4 78 66.7 
Secondary 
or Higher 
15 53.6 9 32.1 15 24.6 39 33.3 
 
I - insulin, O - oral antidiabetic agents; I+O - Insulin and oral antidiabetics; F – feminine; 
M – masculine. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Characterization of the sample for the values of HbA1c, number of monthly 
capillary 
 
 
Diabetes Therapy 
I O I + O Total 
p 
(Kruskal-
Wallis) 
 
 
 
HbA1c 
Mean 8.3 7.2 8.2 8.0  
 
 
0.01 
Median 8.2 7.1 7.8 7.7 
25
th
 
Percentile 
7.1 6.3 7.0 6.9 
75
th
 
Percentile 
9.1 8.2 9.0 8.8 
Standard 
deviation 
1.5 1.5 1.6 1.6 
 
 
Number of 
capillary 
glycemia/month 
Mean 69 24 48 47  
 
 
<0.0005 
Median 62 19 47 40 
25
th
 
Percentile 
46 9 29 26 
75
th
 
Percentile 
86 32 59 62 
Standard 
deviation 
33 21 28 32 
 
 
 
Age 
Mean 61 63 62 62  
 
 
0.70 
Median 66 67 63 65 
25
th
 
Percentile 
48 60 55 54 
75
th
 72 72 70 71 
 
 
Percentile 
Standard 
deviation 
15 12 11 12 
 
glycemia and age, and comparison between treatment groups. I - insulin, O - oral 
antidiabetic agents; I+O - Insulin and oral antidiabetics. 
 
Table 3: Multivariate logistic regression analysis (dependent variable = risk of uncontrolled 
diabetes = HbA1c ≥ 7%). Model adjusted for gender, schooling and age. 
 
 
Coef. 
Exp(coef) 
OR 
p 95% CI 
Interaction term: diabetes therapy = 
I+O * number of capillary 
glycemia/month 
-0.014 0.986 0.076 0.971 – 1.001 
Diabetes therapy = O (compared to I) -1.644 0.193 0.003 0.065 – 0.575 
OR: odds ratio; CI: confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Distribution of HbA1c by treatment groups (box plots). I - insulin, O - oral 
antidiabetic agents; I + O - Insulin and oral antidiabetics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Distribution of the number of monthly glycemias per treatment groups (box 
plots). I - insulin, O - oral antidiabetic agents; I + O - Insulin and oral antidiabetics.  In all 
pairwise comparisons, with Bonferroni test, p-value<0.0005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Association between HbA1c and number of monthly glycemias per treatment 
groups. I - insulin, O - oral antidiabetic agents; I + O - Insulin and oral antidiabetics. 
 
 
 
Figure 4: Association between HbA1c and sex by treatment groups. Mann-Whitney test´s 
p-values.  I - insulin, O - oral antidiabetic agents; I + O - Insulin and oral antidiabetics. 
 
 
